April 8th, 2022, Kobe, Japan – TreeFrog Therapeutics, a French-based biotech company aimed at making safer, more efficient and more affordable cell therapies based on induced pluripotent stem cells (iPSCs), today announced the incorporation of its Japanese subsidiary (KK) TreeFrog Therapeutics Japan and the establishment of a lab in Kobe, at the Creative Lab for Innovation Kobe (CLIK). [Read more…]
AASCP to Host Annual Regenerative Medicine Conference on June 17-19, 2022
April 4 2022, MIAMI, Florida — The American Academy of Stem Cells Physicians is excited to be back at The Hyatt Hotel, this June 17-19, 2022. The conference will focus on the latest state-of-the-art techniques, protocols, and research for 2022. “The Academy for Stem Cell Physicians was founded to advance the field of regenerative medicine and to protect patient access to their individual right to tap into their innate healing abilities,” said Dr. Sunny Kim, President of the AASCP. [Read more…]
PeptiGrowth Inc. is launching a novel synthetic TrkB agonist peptide (BDNF alternative)
April 4, 2022, Tokyo, Japan — PeptiGrowth Inc. (Headquarters: Chiyoda-ku, Tokyo, President: Jiro Sugimoto) has successfully developed a novel TrkB agonist peptide which has the equivalent functions to recombinant Brain Derived Neurotropic Factor (BDNF). We will be marketing this product (BDNF alternative) from the beginning of April, 2022. [Read more…]
StemCyte Requests BLA from U.S. FDA for Allogeneic Cord Blood Product
StemCyte, a regenerative cell therapy company, has applied to the U.S. FDA for a BLA for its allogeneic umbilical cord hematopoietic progenitor cell product (HPC-Cord Blood)
StemCyte’s BLA has been accepted for quality review and StemCyte anticipates licensure in 2023
The USPTO Issues a Patent to Cellular Engineering Technologies For Producing Safer Induced Pluripotent Stem Cells
March 24, 2022, Coralville, Iowa — Cellular Engineering Technologies (CET), Inc., an Iowa biotechnology company specializing in cell manufacturing and contract research services, today announced that it has received a patent from the United States Patent and Trademark Office for its virus-free and oncogene-free induced pluripotent stem cell (iPSC) technology. The iPSC technology which was previously published in Future Science Open Access and Regenerative Medicine was developed in collaboration with the John Paul II Medical Research Institute (JP2MRI), a non-profit organization. More recently, the National Institutes of Health awarded CET a SBIR grant to commercialize the technology to provide reproducible iPSC and differentiated neural stem cells that maintain pluripotency and genetic stability during large scale production. [Read more…]
- « Previous Page
- 1
- …
- 33
- 34
- 35
- 36
- 37
- …
- 96
- Next Page »